Mounjaro May Cause Vision Loss; US FDA Warns About Obesity Treatment (Kyodo News)

The FDA announced that GLP-1 receptor agonists used to treat obesity and type 2 diabetes may cause sudden vision loss.

Full text unavailableWorking from the headline and excerpt

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

The FDA announced that GLP-1 receptor agonists used to treat obesity and type 2 diabetes may cause sudden vision loss.

It pointed to the possibility that use of GLP-1 receptor agonists may be linked to a risk of vision loss.

At a glance

Drug typeUse of GLP-1 receptor agonists is covered

Target conditionObesity treatments and type 2 diabetes drugs are covered

Announcement dateOn the 9th, the FDA issued a warning

Reference information. Every claim resolves to something the story actually named.

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

google.comNews

AgreesOpen

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.

Mounjaro May Cause Vision Loss; US FDA Warns About Obesity Treatment (Kyodo News) | News